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Fc receptors  1 (FcR) recognize the Fc domain of IgG and are found on macrophages, 
lymphocytes, and polymorphonuclear leukocytes (for reviews see Kerbel and Davies 
[1]  and  Dickler[2]).  These  receptors  enable  the  effector cells  to  recognize foreign 
antigens  to  which  antibodies  are  bound  and  may  also  play  a  role  in  immune 
responsiveness (3). Although there have been reports of isolation of FcR from various 
cell types, there is as yet no general agreement on structure or properties. Peptides 
with apparent molecular weights ranging from 125,000 to 28,000 have been isolated 
by affinity chromatography on antibody-coated columns  (4-9).  Indeed, it has been 
suggested  that  FcR  may not  be  a  protein  at  all,  but  represent  only hydrophobic 
interaction of immunoglobulin Fc domains with membrane phospholipid (10). 
The situation is further complicated by the presence of 2 Fc receptors on mouse 
macrophages and macrophage-like cell lines, distinguished by their protease sensitivity 
and  specificity for different  mouse  IgG  subclasses.  FcRI,  which  is  inactivated  by 
trypsin, binds  monomeric and  immune  aggregates of IgG2a,  whereas  FcRII  binds 
immune aggregates of mouse IgG 1 and IgG2b and is unaffected by trypsin or pronase 
(11-15). 
Monoclonal antibodies with defined specificity (16) offer a new method with which 
to analyze the structure and function of well-defined antigens. To examine the nature 
and  specificity of Fc receptors, I  isolated and  characterized a  monoclonal rat anti- 
FcR antibody. This antibody inhibits the rosetting of antibody-coated erythrocytes to 
macrophages, macrophage-like cell lines, and lymphocytes, and binds to a macrophage 
cell line, J774, but not to a set of variants which lack FcRII (17). 
Materials and Methods 
Cell  Culture.  The P388D~ macrophage line,  P388 lymphoma, J774 macrophage cell line, 
and FcRII-deficient variants ofJ774 were grown as described previously (11, 12, 17). El-4 Bu 
was provided by the Cell Distribution Center (Salk Institute, San Diego, Calif.); TLX-9, PU5.1, 
* Supported in part by grants from the National Institutes of Health (AI 14602), Biomedical Research 
Support  grant  5-S07-RR-07065,  the Jane Coffin Childs Memorial  Fund,  and  the Andrew W.  Mellon 
Foundat ion. 
1 Abbreviations used in this paper." aMEM, alpha-modified minimum Eagle's medium; DNP, dinitrophenyl; 
DMEM, Dulbeeco's modified Eagle's medium with 4.5 g/liter of glucose;  E, sheep erythrocytes; Eox, ox 
erythrocytes; E'rNP, TNP-derivatized sheep erythrocytes; FcR, Fc receptor; HIFBS, heat-inactivated fetal 
bovine serum;  HIHS,  heat-inactivated horse serum;  PBS,  phosphate-buffered saline;  PBS-BSA,  PBS 
containing 1 mg/m  I bovine serum albumin; PMN,  polymorphonuelear leukocyte; TNP,  trinitrophenyl; 
TRITC, tetramethyl rhodamine isothiocyanate. 
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and P388 were obtained from Dr. Carl Nathan  (The Rockefeller University, New York); and 
WEHI-231 and L5178Y were a  gift of Dr. Peter Ralph (Sloan-Kettering Institute, Rye, New 
York). All cell lines were grown in alpha-modified minimum Eagle's medium (aMEM, K. C. 
Biological Inc., Lenexa, Kans.) supplemented with 10% fetal bovine serum (Flow Laboratories, 
Inc.,  Rockville, Md.)  heat  inactivated at  56°C  for 30  min  (heat-inactivated bovine serum 
[HIFBS]), 100 U/ml penicillin, and  100 pg/ml streptomycin. PU5.1  and WEHI-231 required 
for growth, in addition, 5  ×  10  -5 M  2-mercaptoethanol. P3U1, a derivative of P3-x6-Ag8 (16) 
which  does  not  make  heavy chains, was  kindly provided by  Dr.  Matthew  Scharff (Albert 
Einstein Medical School, New York) and maintained in Dulbecco's modified Eagle's medium 
with  4.5  gm/liter of glucose (DMEM)  (Grand Island Biological Co.,  Grand  Island, N.  Y.) 
supplemented with 10% HIFBS and  10% heat-inactivated horse serum (HIHS)  (Flow Labora- 
tories, Inc.), penicillin, and streptomycin. 
Peritoneal ceils from unstimulated 20-35 gm 2 mice were obtained by lavage as described 
(18).  Mouse  spleen cells were prepared by gently teasing the spleen to obtain a  single cell 
suspension.  Erythrocytes were lysed by incubation for  10  min  in cold 0.17  M  NH4C1.  Rat, 
rabbit, and  guinea  pig peritoneal cells were  obtained  by  lavage 4  d  after  intraperitoneal 
injection of 10 ml (for the rat) or 25 ml of 1% proteose peptone broth. Human  mononuclear 
cells were obtained from peripheral blood by centrifugation on Ficoll-Paque (Pharmacia Fine 
Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.)  as described by Boyum  (19).  Human 
granulocytes were isolated as described by English and Anderson (20). 
Preparation of OpsonizedErythrocytes.  Sheep erythrocytes were incubated with the monoclonal 
anti-E IgG2a UN-2M2  (EIgG2a) or the monoclonal anti-E IgG2b U88 (EIgG2b) (gifts of Dr. 
Betty Diamond, Albert Einstein Medical School, Bronx, N. Y.) at nonhemagglutinating titer 
(21).  Ox erythrocytes (Eo~) were opsonized with a  purified rabbit anti-Eox IgG as previously 
described (22).  E derivatized with trinitrophenyl (TNP) groups were prepared as described by 
Rittenberg and Pratt (23), and were opsonized (21) with a nonhemagglutinating concentration 
of CD~F1 mouse (BALB/c ×  DBA/2) anti-dinitrophenyl (DNP) IgG1. 
Cell Fusion  to Produce Monoclonal  Antibodies.  A  female Sprague Dawley rat was primed by 
intraperitoneal injection on 6  ×  10  7 viable J774 cells, boosted 2 wk later by intraperitoneal 
injection of a mixture of 3  ×  10  7 J774 and 3  ×  10  v P388D] cells, and sacrificed 3 d later. The 
spleen was teased and  erythrocytes in  the single cell suspension were  lysed in  cold 0.17  M 
NH4CI for 10 min. Washed spleen cells were fused with washed P3U 1 mouse myeloma cells at 
a  10:1 spleen:myeloma cell ratio using 30% polyethylene glycol 1000  (J. T. Baker Chemical 
Co., Phillipsburg, N. J.)  dissolved in DMEM according to Gefter et al. (24).  The products of 
the fusion were dispensed into 100/L1 portions in flat-bottom wells (Costar 3596,  Costar Data 
Packaging, Cambridge, Mass.)  at a  density of 1  ×  10  e P3U1  cells/ml in DMEM  with  10% 
HIFBS and  10% HIHS containing hypoxanthine, aminopterin, and thymidine (100,  10, and 
30 pM,  respectively). The  cells were  fed  every 5  or 6  d  with  50 #1  of medium  containing 
hypoxanthine, aminopterin, and thymidine and screened after 18 d  for production of anti-Fc 
receptor antibody. 
J774 cells (3 ×  103 cells in 5/~1) were seeded in Terasaki trays (Falcon 3034, Falcon Labware, 
Div. of Becton, Dickinson, & Co., Oxnard, Calif.) and incubated for 30 min on ice with 5 #1 
hybridoma supernate, rinsed in phosphate-buffered saline (PBS; NaCI, 0.137 M; KCI 3 mM; 
Na2HPO4,  16 raM; and KH2PO4, 2 mM) and 5 ttl of 1% (vol/vol) EIgG2b in PBS were added. 
After 20 min at 37°C to allow rosettes to form, nonadherent EIgG2b were removed by inverting 
the trays in PBS for 10 min and the wells were then examined for inhibition of rosetting. Cells 
in wells of interest were cloned in 0.5%  sea plaque agarose (Marine Colloids, Inc., Rockland, 
Me.) over a monolayer of rat fibroblasts (Microbiological Associates, Walkersville, Md.) seeded 
initially at 5  ×  104 cells/10-cm diameter tissue culture dish (Falcon 3003,  Falcon Labware, 
Div. of Becton, Dickinson, & Co.). Clones were picked by micropipette, placed in cloning wells, 
and rescreened after adequate growth. 
To make large amounts of monoclonal antibody, 3  ×  106 hybridoma cells were injected 
intraperitoneally into CDzF1 mice (Flow Laboratories, Inc.) which had been injected intraper- 
itoneally  1-3  wk  previously with  0.5  ml  of 2,  6,  10,  16-tetramethyl-pentadecane  (Aldrich 
Chemical Co., Inc., Milwaukee, Wis.). The mice were irradiated with 500 rad (131Cs, 128 rad/ 
min) immediately before injection with the hybridoma cells. The ascites fluid was tapped every 
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Preparation of Immunoglobulins and Proteolytic  Fragments.  Ascites fluid from the 2.4G2 hybridoma 
was adjusted to 45% saturation with  (NH4)2SO4.  The precipitate collected by centrifugation 
was  dissolved in  PBS  and  subjected to  Sephadex G-200  chromatography  (Pharmacia  Fine 
Chemicals, Div.  of Pharmacia Inc.).  The  IgG peak from  the  Sephadex G-200 column  was 
dialyzed against 0.025 M Tris-HC1, pH 8 and 100 mg of protein applied to a 2 X  5-cm column 
of DE-52  (Whatman,  Inc., Clifton, N. J.). The column was eluted with a  500  ml 0-0.5  M 
gradient of NaCI dissolved in 0.025 M  Tris-HCl, pH 8. The 2.4G2 IgG eluted at 0.1 M  NaCI. 
To prepare the Fab fragment, the purified IgG was digested with a  1:100 wt/wt ratio of papain 
for 16 h  at 37°C as described by Porter (25).  The digest was purified on a  DE-52 column as 
described above. The Fab fragment eluted at 0.09 M  NaCI. 
The  mouse  IgG2a myeloma protein  LPC-1  and  rabbit  anti-DNP  IgG were  prepared  as 
described previously (11,  12). 
CD2F1 mouse anti-DNP IgG was prepared from ascites fluid from mice immunized repeatedly 
with DNP-keyhole limpet hemocyanin as described by Tung et al.  (26).  The anti-DNP IgG 
from the ascites fluid was isolated as described (12).  To isolate IgGx, which does not bind to 
protein A  (27),  anti-DNP IgG (4.5  mg) was passed sequentially over two 0.3-ml columns of 
protein-A Sepharose 4-B (Pharmacia Fine Chemicals, Div. of Pharmacia Inc.). Of the purified 
anti-DNP IgG initially loaded on the column, 0.54 mg of anti-DNP IgG1 was isolated. The 
anti-DNP IgG 1 formed precipitin lines in agar with only goat anti-mouse IgG 1 (IgG 1 antiserum, 
lot 88336; IgG2a antiserum, lot 88570;  IgG2b antiserum, lot 77028,  Meloy Laboratories, Inc., 
Springfield, Va.; IgG3 antiserum, lot 231-70-9, Litton Bionetics, Kensington, Md.). 
Iodinations.  Proteins (50 ~g each) were iodinated with 500 pCi of 12SINa (Amersham Corp., 
Arlington Heights,  I11.) using chloramine T  at  a  molar chloramine T:IgG ratio of 10:1 as 
described (11, 28). Incorporation of 12sI into protein was >50%. 
Immunofluorescence.  Viable adherent cells were seeded on glass coverslips. Nonadherent cells 
in medium without serum were centrifuged (200 g, 10 min) onto 12-mm diameter acid-washed 
coverslips which had previously been incubated for 30 min in 50 pg/ml poly-L-lysine (34,000 
mol wt, Sigma Chemical Co., St. Louis, Mo.), dissolved in PBS, and then rinsed in water. After 
the cells had been centrifuged onto the slips, they were transferred to medium with serum. The 
coverslips were then incubated with 2.4G2 IgG (30/zg/ml) or a  1:200 dilution of ascites in PBS 
containing 1 mg/ml of crystallized bovine albumin (PBS-BSA) for 30 min at 4°C. After gentle 
rinsing, the cells were stained for 30 min at 4°C with a  1:20 dilution ofa tetramethyl rhodamine 
isothiocyanate (TRITC)-rabbit anti-rat IgG F(ab')2 reagent (N. L. Cappell Laboratories, Inc., 
Cochranville, Pa.), rinsed, and fixed in  10% buffered neutral formalin. Cells were screened for 
surface IgM by staining with a  fluorescein isothiocyanate-coupled rabbit anti-/~ reagent (29). 
Specimens were viewed with a X  63 oil immersion lens on a Zeiss microscope with epifluoresc- 
ence optics (Carl Zeiss, Inc., N. Y.). 
Immunoelectrophoresis and Ac!ylamide Gel Electrophoresis.  Immunoelectrophoresis was performed 
in 2% agar, 0.05 M Na barbital, pH 8.2, and the slide developed with a rabbit anti-rat IgG (N. 
L. Cappell Laboratories, Inc.). Sodium dodecyl sulfate (SDS) polyacrylamide  gel electrophoresis 
was performed as described by Neville (30) using 1-mm thick slab gels with a 4-1 I% gradient 
of acrylamide. Sample buffer was 50 mM Na2COa pH 8.4, 2% SDS, 50 mM dithiothreitol, 12% 
wt/vol sucrose. 
Binding Studies.  Washed cells (5-10  X  105) were incubated in suspension with 125I-2.4G2 
IgG in PBS-BSA at 4°C for 1 h. After dilution with 3 ml cold PBS-BSA, they were centrifuged 
at 500 g for 5 rain, and the supernate was removed. The pellet was washed with 3 ml of PBS- 
BSA, recentrifuged, and the tubes assayed for radioactivity after removal of the supernate. The 
washing removed 99.4%  of input radioactivity from both empty tubes and negative cell lines. 
Experiments were usually carried out using a  constant trace amount  of 125I-2.4G2 IgG with 
variable amounts of nonradioactive 2.4G2 IgG so that the specific activity was between 104 and 
106 cpm//~g. 
Results 
Characterization  of the Monoclonal  2.4G2 IgG.  The screen which  was used  to search 
for an  anti-FcR  monoclonal  antibody was  inhibition  of the  binding of EIgG2b  to 
J774  cells seeded  in  Terasaki  plates.  Of five separate  fusions  with  immunized  rat JAY C.  UNKELESS  583 
FI6.  1.  Characterization  of the purified 2.4G2 IgG molecule and  Fab  fragments. Samples were 
reduced with 50 mm dithiothreitol and boiled for 1 min before SDS polyacrylamide gel electropho- 
resis. Lanes A and B, Coomassie Brilliant Blue stain;  lanes C-F, autoradiogram  of 12~I-proteins. 
Lane A, intact 2.4G2 IgG; lane B, Fab fragment; lane C, 125I-2.4G2  IgG; lane D, 12SI-Fab; lane E, 
final supernate from J774-adsorbed 12~I-Fab (Table I); lane F, 125I-Fab  adsorbed to J774 cells in first 
cycle (Table I). Autoradiograms were exposed on Dupont Cronex x-ray film for I d. Standards used 
to determine molecular weights were soybean trypsin inhibitor (21,500 daltons), ovalbumin (43,000 
daltons), and BSA (68,000 daltons). 
spleen  cells,  which  yielded  >1,000  hybridoma  clones,  only  one  hybridoma-making 
antibody  of the  desired  specificity  was  isolated,  2.4G2.  Of  the  >100  clones  with 
secreted  anti-macrophage  antibodies,  determined  by immunofluorescence,  none had 
any effect on EIgG2b rosette formation. 
The purified  2.4G2 hybridoma antibody had one type of heavy chain, of apparent 
mol wt 52,000, and two different types of light chains, one of which derived from the 
P3U1  myeloma,  and  one  which  came  from  the  rat  spleen  B  cell  (Fig.  1 A).  After 
digestion with  papain  there was no visible  intact  heavy chain,  and  two heavy chain 
fragments,  of apparent  mol  wt  30,000  and  26,000  were  seen  (Fig.  1 B). Judged  by 
Coomassie  Blue  staining,  the  relative  abundance  of these  two  new  fragments  was 
approximately the same as the relative abundance of the two light chains, which were 
not altered in electrophoretic mobility after papain digestion. This result suggests that 
the  type  of light  chain  associated  with  the  heavy  chain  determined  the  extent  of 
papain  digestion of the latter. 
To ascertain which type of light chain in the hybridoma IgG was of rat spleen cell 
origin,  the  purified  Fab  fragments  were  iodinated,  and  sequential  adsorptions  were 
carried out with either J774 cells or a  non-FcR-bearing lymphoid line,  L5178Y. The 
results  (Table  1) show that >50% of the 125I incorporated into the Fab fragments was 
bound to J774 cells. The amount bound in the third adsorption was only 20% of that 
bound  in  the  first.  Little  radioactivity  (0.5%  of the  initial  125I) was  adsorbed  by 
L5178Y cells. The t25I-Fab adsorbed to the first aliquot ofJ774 cells and the supernate 
from  the  final  adsorption  were  reduced  and  analyzed  by  SDS  polyacrylamide  gel 
electrophoresis.  The  autoradiogram  (Fig.  1 E)  shows  clearly  that  the  more  rapidly 584  MONOCLONAL ANTI-Fc RECEPTOR  ANTIBODY 
TABLE I 
Sequential Adsorption of 1251-2.  4G2 Fab Fragments by J774 and L5178Y Cells 
Treatment  J774 macrophage cell line  Lymphoma 
cpm × 10  -5 
Initial  4.51  4.66 
Adsorption 1  1.39  0.014 
Adsorption 2  0.81  0.005 
Adsorption 3  0.25  0.004 
Total washes  0.50  0.64 
Final supernate  1.57  4.00 
Aliquots of 12sI-2.4G2 Fab  (5 btl, 20 /xg/ml, 5  ×  103 cpm/ng)  diluted with 20 #1 of PBS-BSA were 
sequentially adsorbed three times with fresh  portions ofJ774 or L5178Y cells (2 ×  105 cells per adsorption). 
The cell pellet after each cycle was resuspended and washed with 1 ml of cold PBS-BSA. Adsorption 1 of 
J774 cells and the final J774 supernate were subjected to polyacrylamide  gel electrophoresis  and are shown 
in Fig. 1, F and E, respectively. 
migrating H-chain fragment was adsorbed from the azsI-Fab (Fig.  1 D). Only the Fab 
fragments composed of the rapidly migrating heavy chain fragment--light chain pair 
bound to the J774 cells (Fig.  1 F). Assuming that the homologous rat light chain-rat 
heavy chain combination results in  the formation of the antibody binding site, this 
experiment defined the rat light chain as the more rapidly migrating peptide. 
The intact hybridoma antibody was tested by Ouchterlony diffusion against goat 
anti-IgM,  IgE, IgA, and  IgG antisera,  generously supplied  by Doctors Teruko and 
Kimishige Ishizaka (Johns Hopkins School of Medicine, Baltimore, Md.), and formed 
a  precipitin  line only with  anti-IgG (not  shown).  The 2.4G2  IgG does  not  bind  to 
protein A (not shown). Of the four rat IgG subclasses, Medgyesi et al. (31) have shown 
that only rat IgG2a and IgG2b fail to bind to protein A. However, the assignment of 
the hybridoma IgG to either of these subclasses must be provisional, because both are 
reported to migrate rapidly towards the cathode  (32), and 2.4G2 IgG migrates very 
slowly relative to the bulk of rat IgG (Fig. 2). 
Inhibition  ofMacrophage FcR.  Preincubation ofJ774 cells with different dilutions of 
2.4G2  ascites  fluid  followed  by  rinsing  to  remove  unbound  hybridoma  antibody 
resulted  in striking inhibition  of EIgG2b binding to Fc receptors  (Figs.  3b, c). This 
inhibition  was observed even at a  1:16,000  dilution of the original ascites  (Fig.  3 d). 
To test the possibility that the inhibition of the Fc receptors was not a  result of the 
hybridoma binding to the cell surface via the antibody combining site but a result of 
the blockade of Fc receptors by the Fc domain of the hybridoma antibody, the Fab 
fragment of 2.4G2 IgG was prepared. 
The Fab fragment of 2.4G2 IgG inhibited the binding of EIgG2b to macrophages 
(Fig.  4b)  relative to  the  control  (Fig.  4a),  although  not  to  the  same extent  as  the 
intact hybridoma antibody (Fig. 4c). The monovalent Fab fragment probably has a 
lower affinity for the antigenic site than the bivalent  2.4G2  IgG, and thus does not 
inhibit EIgG2b rosette formation as efficiently. Similar results were obtained using E 
derivatized with TNP  groups which  were then  coated with  mouse anti-DNP  IgG1 
(ETNP IgG1). These erythrocytes bound avidly to J774 cells (Fig. 4 d) but did not bind 
to J774  cells  preincubated  with  either  the  Fab  fragment  (Fig.  4e)  or  the  intact 
hybridoma antibody (Fig. 4 f). Thus, the inhibition of rosetting of EIgG2b and ETNP 
IgG1  to  macrophages  by  the  monoclonal  antibody  was  a  result  of the  antigenic JAY  C.  UNKELESS  585 
Fro.  2.  Immunoelectrophoresis  of 2.4G2 IgG and rat serum. The top well was loaded with 15 #l 
of 1.15 mg/ml 2.4G2 IgG, the bottom well with 15 p.l normal rat serum. After electrophoresis, the 
center well was filled with rabbit anti-rat IgG, and developed overnight. 
binding site of the antibody, and not to immune blockade of Fc receptors by the Fc 
domain. 
A  different pattern of Fc receptor inhibition by the hybridoma antibody and Fab 
fragment was  observed when  EIgG2a binding  to  macrophages was  tested.  Rosette 
formation with EIgG2a was blocked by preincubation with 2.4G2  IgG (Fig.  4j)  but 
was unaffected by preincubation with the Fab fragment (Figs. 4 g, h). We also tested 
the binding of monomeric l~sI-IgG2a (11)  to J774 cells after preincubation of the J774 
cells with  2.4G2  IgG or  the  Fab  fragment.  There  was  no  inhibition  by the  F(ab) 
fragment, and the intact hybridoma antibody inhibited binding of monomeric IgG2a 
totally  (not  shown).  Thus,  the  inhibition  of IgG2a  and  EIgG2a  binding  by  the 
hybridoma  antibody  was  a  result  of Fc  domain  blockade  of the  FcRI  site.  The 
antigenic site to which 2.4G2 IgG binds is unrelated to the IgG2a-specific Fc receptor 
site. It appears likely that mouse IgG2a, whether aggregated or monomeric, binds to 
a receptor distinct from that which binds aggregated IgG2b, as discussed by Diamond 
et al.  (14). 
Binding of 2. 4G2 IgG to Macrophage FcR Variants.  A set of variants of the J774 mouse 
macrophage cell line  had  been previously isolated which  bound  only  1-3  E  coated 
with  IgG2b compared to  25  or more for the J774  parent.  The  variants  lacked  the 
trypsin-resistant FeR for IgG2b aggregates (FcRII), but not FcRI which binds mouse 
IgG2a (17).  The binding of the 2.4G2 IgG to these variants and the parent  cell line 
was  examined  by  immunofluorescence  using  a  TRITC-rabbit  anti-rat  IgG F(ab')2 
reagent  to  stain  viable cells  first  incubated  with  2.4G2  IgG  (Fig.  5).  The  variants 
showed a  dramatic lack of immunofluorescence compared to the parent,  indicating 
the absence of the antigenic determinant recognized by 2.4G2 IgG. 
These experiments were repeated using a  quantitative assay of the binding of a2sI- 
2.4G2 IgG to the same cell lines. A preliminary experiment established that there was 
no detectable dissociation of bound 12~I-2.4G2 IgG from the surface ofJ774 cells over 
a  3-h period (not shown). The results of the quantitative binding experiment (Fig. 6) 
confirmed  the  immunofluorescence  data.  The  parent  J774  cells  bound  0.15  /~g of 
2.4G2  IgG per  106  cells,  ~600,000  IgG molecules per  macrophage.  The  binding  to 
J774 cells of 12SI-Fab fragment was similar to the intact 2.4G2 IgG except that slightly 
less of the Fab fragment bound at saturation. Trypsinization of the J774 cells had no 
effect on subsequent binding of 125I-2.4G2 IgG. 
Because the variants were all  isolated from independent  mutagenizations ofJ774 586  MONOCLONAL  ANTI-Fc RECEPTOR  ANTIBODY 
Fie.  3.  Inhibition of rosetting with EIgG2b by preincubation ofJ774 cells with 
2.4G2  ascites  fluid.  A,  control;  B,  1:1,000 ascites  dilution; C,  1:4,000 ascites 
dilution; D,  1  : 16,000 ascites dilution. J774 cells on coverslips were preincubated 
for 1 h on ice with ascites dilutions, rinsed in PBS, and incubated with 1% EIgG2b 
at 37°C for 20 min. 
cells and were all markedly defective in 2.4G2 IgG binding, these results strengthened 
the  probability  that  the  2.4G2  IgG  was  directed  against  the  FcRII  receptor  or  a 
closely associated structure.  Assuming that  each 2.4G2 IgG molecule can inhibit two 
binding sites,  the number  of FcRII sites on J774  cells was  ~1.2  ×  106 per cell, four 
times greater than the number  of IgG2a FcRI sites  (3.1  X  105) on J774  (17). 
Binding  of  2.4G2  IgG  and  Inhibition  of  FcR  on  Macrophages  and  Other Cells.  An 
advantage of monoclonal sera over conventional antisera is that  they can be used to JAY  C.  UNKELESS  587 
FIG. 4.  Binding of E coated with different subclasses  of mouse lgG to J774 cells preincubated with 
2.4G2 IgG or Fab. A-C, rosetting of EIgG2b on A, J774 ceils; B,J774 cells preincubated with 2.4G2 
Fab; C, J774 cells preincubated with 2.4G2 IgG. D-F, rosetting of ETNplgG1 on D, J774 cells; E, 
J774 cells preincubated with 2.4G2 Fab; F, J774 cells preincubated with 2.4G2 IgG. G-J, rosetting 
of EIgG2a on G, J774 ceils; H, J774 cells preincubated with 2.4G2 Fab; J, J774 cells preincubated 
with 2.4G2 IgG. Preincubations were for 30 min at 4°C with 30 #g/ml of IgG or Fab in PBS-BSA. 
define a unique antigenic determinant on a  variety of cell types without the necessity 
of adsorption to remove unwanted specificities. First a  series of cell populations was 
screened  for  binding of 2.4G2  IgG  by  immunofluorescence. Binding was  detected 
using a  TRITC-rabbit  anti-rat  IgG  F(ab')2  as  the  second  reagent.  In  this  assay Fro.  5.  Binding of 2.4G2  IgG to j774 cells and FcRII variants detected by immunofluorescence. 
Photographs on  the  left were taken  with  phase-contrast optics,  photographs on  the  right, with 
epifluorescence optics.  A, J774  cells;  B,  ICR7.1  cells; C,  MNNG1.2  cells;  D,  MNNG  6.31  cells. 
Fluorescence photographs were all 3-min exposures. 
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Fxe. 6.  Quantitative  analysis of binding of 125I-2.4G2 IgG to J774 cells and  different FcRII 
variants. Cells (10  n) were incubated for 1 h at 4°C with 0.25 ml of PBS-BSA containing a constant 
amount of 125I-2.4G2 IgG (5  X  103 CPM, 5.6  X  10  a CPM/ng) and nonradioactive 2.4G2 IgG as 
noted. The cells were then washed and assayed for bound radioactivity. Radioactivity bound to 
serum-coated empty tubes was subtracted. 
589 
macrophages, -40% of spleen cells, the J774 and P388D1  macrophage-like cell lines, 
and  the  P388  lymphoma bound  2.4G2  IgG  (not  shown).  Negative cells  included 
thymocytes, L-cells, and the P3U1  myeloma. To obtain more quantitative data, the 
binding of 125I-2.4G2  to a  series of mouse lymphoid lines was studied  (Fig.  7).  Cells 
binding  2.4G2  IgG were the  P388  lymphoma, PU5.1,  and  WEHI-231.  Cells which 
did not bind 2.4G2  IgG (giving a  background  of binding identical  to serum-coated 
empty tubes)  were  L5178Y,  EL-4,  TLX-9,  thymocytes, and  splenic  dendritic  ceils 
isolated by the procedure of Steinman et al. (33). 
In addition to screening for the binding of 2.4G2 IgG, the ability of the monoclonal 
antibody to inhibit rosetting was also examined. These experiments were done using 
opsonized ox erythrocytes (EoxIgG), which can be coated with a higher density of IgG 
than  sheep  erythrocytes without  agglutinating  (34)  and  thus  are  a  more  sensitive 
indicator than EIgG for FcR. Table II shows that  the cells which  bound 2.4G2 IgG 
formed rosettes (J774, P388, PU5.1, and WEHI-231) and that preincubation with the 
monoclonal  antibody  blocked  the  binding  of EoxIgG. The  extent  of rosetting  was 
roughly  proportioned  to  the  amount  of 2.4G2  IgG bound.  Rosette  formation  by 
WEHI-231, which bound only 30,000 molecules of the hybridoma IgG per cell, could 
not  be demonstrated  using  EIgG, and  was weak even with  EoxIgG. The  extent  of 
rosetting  by  EL-4,  L5178Y,  TLX-9,  and  thymocytes was  very  low  and,  with  the 
exception  of thymocytes, where  ~1%  of the  cells  formed  rosettes  with  >I1  E,  no 
heavily rosetted cells were found. 











I  I 
10  20 
2.4G2 IgG (~jg/ml) 
CJ774 




, ,.it  [TLX-9 
1  ILSI78Y 
30  IEL-4 
[ThymoCytes 
Fro.  7.  Quantitative  analysis of binding of l~sI-2.4G2 IgG to different cell lines.  Procedures were 
as detailed in Fig. 6. 
TABLE  II 
Inhibition of EoxlgG Rosette Formation on Lymphoid and Macrophage Cell Lines by 2. 4G2 IgG 
Phag-  Lyso-  Sur- 
Cell  ocyto-  zyme  face  Thy-1  Classification  Preincuba-  Ro-  Bound 
sis of  secre-  tion  settes  EoxlgG 
latex  tion  Ig 
% of total per cell 
J774 (12, 46, 48)  +  +  -  -  Macrophage  -  85  9.8 
2.4G2 IgG  15  1.0 
P388 (47, 48)  ....  Null lymphoid  -  73  5.5 
2.4G2 IgG  12  0.4 
PUS.1  (48, 49)  ....  (B cell)*  -  79  6.3 
2.4G2 IgG  8  0.3 
WEHI-231  (50)  -  -  +  -  B cell  -  53  3.0 
2.4G2 IgG  19  0.8 
EL-4 (13, 47, 48)  -  -  -  +  T  cell  -  16  0.6 
2.4G2 IgG  10  0.4 
L5178Y (13, 51)  -  -  -  +  T  cell  -  11  0.4 
2.4G2 IgG  10  0.4 
TLX-9  (51)  -  -  -  ?  Lymphoid  -  3  0.1 
2.4G2 IgG  4  0.2 
Thymocytes  -  -  -  +  T  cell  -  l 1  0.6 
2.4G2 IgG  3  0.1 
Ceils were preincubated in PBS-BSA containing 30 #g/ml  of 2.4G2 IgG or Fab for 30 min on ice. 
After  washing by centrifugation, a  40-fold excess  of Eo,IgG  was  added  and  the  mixture  of cells  was 
centrifuged to form a  pellet in round-bottom  plastic tubes. After a  1-h incubation on ice, the cells were 
gently resuspended by pipette and counted. Cells binding three EoxlgG or more were counted as rosettes. 
* Although PU5.1  has been reported to have surface #-chain, none was detected on the ceils I  tested. JAY  C.  UNKELESS  591 
TAnLE  III 
Inhibition of EoxlgG Binding in Spleen and Peritoneal Cell Populations by 2. 4G2 IgG and the 2. 4G2 Fab 
Fragment 
Strain of mouse  H-2 haplo-  Cell population  Preincubation  Rosettes  EoxIgG  per  type  cell 
% of total 
C57/B 16  b  Peritoneal  Control  27  2.0 
Peritoneal  2.4G2 IgG  4  0.2 
Spleen  Control  47  3.2 
Spleen  2.4G2 IgG  5  0.3 
DBA/2J  d  Peritoneal  Control  21  1.4 
Peritoneal  2,4G2 IgG  4  0.2 
Spleen  Control  38  2.6 
Spleen  2.4G2 IgG  7  0.4 
C3H/HeN  k  Peritoneal  Control  38  2.7 
Peritoneal  2.4G2 IgG  2  0.1 
Peritoneal  2.4G2 Fab  7  0.3 
BALB/c  d  Peritoneal  Control  72  6.3 
Peritoneal  2.4G2 IgG  13  0.6 
Peritoneal  2.4G2 Fab  19  1.5 
Spleen  Control  44  2.9 
Spleen  2.4G2 IgG  21  1.0 
Spleen  2.4G2 Fab  16  0.7 
NCSR  --  Peritoneal  Control  16  1.1 
Peritoneal  2.4G2 IgG  2  0.1 
Spleen  Control  40  2.4 
Spleen  2.4G2 IgG  4  0.3 
Protocol for rosette formation was as detailed in Table II. 
on cells of the H-2d haplotype (because the J774  cells used  for immunization of the 
rat are of BALB/c origin) peritoneal cells and spleen cells from a  number of different 
inbred mouse strains were screened. The results (Table III) show that ~40% of spleen 
cells from all strains tested formed EIgG rosettes, which is in agreement with previous 
results (35-36). The percentage of EoxIgG rosetting cells in the resident peritoneal cell 
population was more variable, but preincubation with 2.4G2 IgG inhibited formation 
of EoxIgG  rosettes  in  all  cases  in  both  spleen  cells  and  resident  peritoneal  cells.  I 
attempted to screen for mouse neutrophil Fc receptor inhibition but could not obtain 
satisfactory rosetting  in  controls  using  cells from  mouse  peripheral  blood,  or  from 
mouse peritoneal cavity 17 h  after injection of 1 ml of thioglycollate medium. 
Fc Receptors  on  Cells of Other Species.  Peritoneal cells from  rabbit, guinea pig, and 
rat,  as  well  as  human  peripheral  blood  mononuclear  cells and  granulocytes,  were 
tested  to  see  if the  2.4G2  IgG  inhibited  binding  of EIgG.  Preincubation  with  the 
hybridoma antibody did not  block EIgG rosetting on  any of these cells. There was 
some  binding over background  of 12~I-2.4G2 IgG to guinea pig peritoneal cells, but 
this appeared to be Fc domain-mediated because there was no binding of the 125I-Fab 
fragment. Thus,  the antigenic site recognized by the hybridoma antibody is specific 
for a  mouse determinant. 
Discussion 
The  striking ability of macrophages  and  some  lymphocytes to  bind  erythrocytes 
coated with IgG is a  result of the presence of Fc receptors on the plasma membranes 
of these cells. These receptors confer specificity in the phagocytosis of antibody-coated 592  MONOCLONAL ANTI-Fc RECEPTOR ANTIBODY 
particles by macrophages (37), and in the destruction of target cells by lymphoid K 
cells and macrophages (38) in the presence of an appropriate anti-target cell antibody. 
The  function  of the  FcR  on  B  lymphocytes  is  not  clear,  but  the  interaction  of 
complexes with FcR may be involved in regulation of the immune response (1-3). 
The  development  of the  technique  for making  monoclonal  antibodies  (16)  has 
opened exciting possibilities for dissection of immunogenic cell surface components, 
and  I  felt  this  approach  might  be  fruitful  for  studying  FcR.  The  search  for  a 
monoclonal anti-FoR antibody was based on the assumption that such an IgG would 
block the binding of EIgG2b which were used in the screening assay. There have been 
reports of inhibition of Fc receptors on B cells by IgG and F(ab')2 fragments directed 
against  a  variety of surface markers  including  Ia,  H-2D,  H-2K, Ly4.2, and  mouse 
immunoglobulin (see Halloran and Schirrmacher [39] for review). Inhibition of mouse 
macrophage FcR by Fab  or F(ab')2  fragments of anti-mouse  macrophage  IgG has 
also  been  reported  (40).  Because  it  is  unlikely  that  all  of these  allergeneic  and 
xenogeneic sera are directed against  FcR, it appears more likely that inhibition is a 
result of steric blockage of the receptors or to perturbation of the membrane in an as 
yet undefined manner. A series of monoclonal antibodies I  have isolated, which are 
directed against various macrophage surface determinants, have no inhibitory effect 
on  either FcR  or the  C'  receptor, suggesting  that  the  polyvalent character of the 
allogeneic and xenogeneic sera mentioned above may be an important factor in their 
ability to inhibit FcR. 
The evidence that  the monoclonal IgG secreted by the 2.4G2  hybridoma has an 
anti-FcR antigenic specificity rests in part on the binding of the antibody to different 
cell types. A series of independently isolated variants of the J774 macrophage-like cell 
line which were unable to bind EIgG2b  (17)  bound 5% as much 2.4G2 IgG as the 
parent clone bound. Also, all cells which failed to form EoxIgG rosettes (L-cells, TLX- 
9, P3U1, L5178Y, EL-4, and thymocytes) failed to bind 125I-2.4G2 in a  quantitative 
and  sensitive binding  assay.  Conversely, cell  lines  which  did  form  EoxIgG rosettes 
(P338,  P388D1, J774,  PU5.1,  and  WEHI-231)  bound  125I-2.4G2 IgG.  Mixed  cell 
populations from mouse peritoneal cavity or spleen, after preincubation with 2.4G2 
IgG, did not form rosettes with EoxIgG. The inhibition of FcR on a variety of different 
cell types, from different H-2 backgrounds, and the absence of the antigen-recognized 
by the hybridoma antibody on  FcRII  negative mutants  of a  macrophage cell line 
both suggest  strongly that  the  2.4G2  IgG  recognizes an  antigenic  determinant  on 
FcRII. 
The inhibition of binding of EIgG2b and EIgG 1, but not EIgG2a by preincubation 
of macrophages with the Fab fragment of the hybridoma antibody demonstrates that 
the two macrophage Fc receptors are different antigenically. The result is consistent 
with  the  report  by  Diamond  et  al.  (14)  that  binding  of EIgG2a  and  EIgG2b  is 
inhibited only by the homologous subclass of aggregated mouse IgG, but  is not  in 
agreement with Heusser et al. (13), who concluded that the trypsin resistant receptor 
bound  aggregated  antibody of all  mouse  subclasses.  The  inhibition  of IgG2a  and 
EIgG2a binding by preincubation of macrophages with the intact hybridoma anti- 
body is apparently a  result of immune blockade of the FcRI site by the hybridoma 
IgG Fc domain. 
An important result of these experiments is the definition of a common determinant 
on macrophages and some lymphoid cells.  The relative ease with which rabbit IgG- JAY  C.  UNKELESS  593 
coated E (which bind via both FcRI and FcRII [14,  17]) form rosettes on macrophages 
compared to lymphoid cells is probably a  result of the presence of FcRI on macro- 
phages and possibly to a  higher density of FcRII sites.  Lymphoid cells which bind 
monomeric IgG2a poorly (13) may not express FcRI. One of the earliest studies of B 
cell, FcR demonstrated an inhibition of binding of mouse anti-fowl IgG l~I-fowl IgG 
complexes by IgG1  and  IgG2b, but  not  IgG2a  (41).  Heusser et al.  (13)  found that 
monomeric IgG2a did not bind to lymphocytic lines and that the order of binding of 
aggregated  mouse subclasses  of IgG was  IgG1  =  IgG2b >  IgG2a.  Many  binding 
studies have been performed with heat or bis-diazotized benzidine-induced aggregates, 
and  it  is not  altogether clear that  such  large aggregates bind  in similar  fashion to 
immune complexes. The specificity of FcRII for IgG1 and IgG2b complexes, but not 
IgG2a complexes, appears to be the same as the specificity of FcR on mouse B cells. 
There are numerous reports of the presence of FcR on some cells of T-lymphocyte 
origin (42-44). Anderson and Gray (44) found that 20-40% of thymocytes bound 12sI- 
mouse IgG2b aggregates by autoradiography. Similar results were reported by Stout 
and Hertzenberg (43) who reported 10% of thymocytes were FcR  + by use of fluores- 
cinated keyhole limpet hemocyanin (KLH)-anti-KLH complexes and the fluorescence 
activated cell sorter. Basten et al. (42) could demonstrate thymus cell FcR only with 
aggregated human IgG and not with immune complexes or myeloma protein aggre- 
gates.  In the present  study, thymocytes did not  form EoxIgG rosettes, nor did  they 
bind 2.4G2 IgG. However, there is no doubt that there are Thy-1 positive lymphoid 
lines which bear FoR (13, 45, 50), and it is possible that a subpopulation ofT cells in 
the spleen have FcR which bear the 2.4G2 antigenic determinant. Cell fractionation 
studies are in progress to resolve this question. 
Studies are planned to isolate and characterize the antigen recognized by the 2.4G2 
IgG and to reconstitute, if possible, the FcRII molecule in lipid micelles. The antibody 
will also aid in understanding the role of FcR in the biological function of cells which 
bear the determinant. 
Summary 
To investigate the antigenic relationship between the macrophage and lymphocyte 
Fc receptors (FcR), a  monoclonal antibody capable of blocking mouse macrophage 
Fc receptors was selected. Hybrids were formed by fusing the P3U 1 mouse myeloma 
and spleen cells from a rat immunized with the mouse macrophage-like cell lines J774 
and  P388D1.  The  Fab  fragment  of the  monoclonal  IgG  secreted  by clone  2.4G2, 
inhibited the trypsin-resistant  Fc receptor II  (FcRII), which i  s specific for immune 
aggregates of mouse IgG1  and  IgG2b,  but  had  no inhibitory effect on the trypsin- 
sensitive Fc receptor I (FcRI), which binds monomeric IgG2a and erythrocytes coated 
with IgG2a. Thus, the monoclonal 2.4G2 IgG appeared to be specific for macrophage 
FcRII. 
Further evidence that the 2.4G2 IgG was directed against FcRII came from binding 
studies of the monoclonal antibody to J774 cells and a series of independently isolated 
variants which do not express FcRII. These variants ofJ774 bound 5% as much of the 
monoclonal antibody as  the parent  line, which  bound  600,000  molecules of 2.4G2 
IgG per cell. 
The antigenic relatedness of mouse lymphocyte FcR to mouse macrophage FcRII 
was demonstrated by the binding of 2.4G2 IgG to FcR-bearing lymphoid cell lines 594  MONOCLONAL  ANTI-Fc RECEPTOR  ANTIBODY 
and the inhibition  of the lymphocyte FcR by the monoclonal antibody. Preincubation 
of spleen cells and peritoneal cells with 2.4G2 IgG likewise inhibited rosette formation 
with ox erythrocytes coated with rabbit IgG. The ability of the  hybridoma IgG to 
inhibit mouse FcRII was independent of the major histocompatibility complex. The 
2.4G2 IgG antigenic determinant was not present on rat, guinea pig, rabbit, or human 
FcR-bearing cells. 
Advice and discussions with Dr. Z. Cohn, Dr. C. Bianco, Dr. C. Nathan, and Dr. S. Silverstein 
were most helpful and stimulating. Ms.  H. Plutner and Ms.  M. McGettigan provided skillful 
technical assistance. 
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